Migraine

Neurology·MeSH: Migraine Disorders

Prevalence

15000.0 / 100K

Incidence

1500.0 / 100K/yr

69 drugs in development·40 companies·34 clinical trials

Drug Pipeline by Phase

Approved(26)

Drug	Company
almotriptan malate	Mylan II B.V. (MYL)
brekiya	Amneal Pharmaceuticals, Inc. (AMRX)
CAMBIA	Assertio Holdings, Inc. (ASRT)
compound yangjiao	Fuss Brands Corp. (FBDS)
divalproex	Teva Pharmaceutical Industries Limited (TEVA)
eletriptan hydro	Mylan II B.V. (MYL)
elyxyb	BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI)
Emgality	ELI LILLY & Co (LLY)
Emgality®	ELI LILLY & Co (LLY)
gelstat migraine	GELSTAT CORP (GSAC)
inFoods® (IBS)	BIOMERICA INC (BMRA)
nurtec odt	PFIZER INC (PFE)
Nurtec ODT/Zavzpret	Royalty Pharma plc (RPRX)
rizaport	INTELGENX TECHNOLOGIES CORP. (IGXT)
Sevedol™	ABBOTT LABORATORIES (ABT)
sumatriptan	Mylan II B.V. (MYL)
sumatriptan	DR REDDYS LABORATORIES LTD (RDY)
Symbravo	Axsome Therapeutics, Inc. (AXSM)
topiramate	Teva Pharmaceutical Industries Limited (TEVA)
topiramate	DR REDDYS LABORATORIES LTD (RDY)
treximet	PERNIX THERAPEUTICS HOLDINGS, INC. (PTX)
treximet	Old API Wind-down Ltd. (ARLZ)
Trokendi XR	SUPERNUS PHARMACEUTICALS, INC. (SUPN)
trudhesa	IPI Legacy Liquidation Co (IMPL)
ubn relief	HEALTHY EXTRACTS INC. (HYEX)
zavzpret	PFIZER INC (PFE)

Phase 3(12)

Drug	Company
Atogepant	AbbVie Inc. (ABBV)
axs-07	Axsome Therapeutics, Inc. (AXSM)
BOTOX	AbbVie Inc. (ABBV)
Botulinum toxin type A	Valneva SE (VALN)
fremanezumab	Teva Pharmaceutical Industries Limited (TEVA)
Galcanezumab	ELI LILLY & Co (LLY)
lasmiditan	ELI LILLY & Co (LLY)
sts101	Satsuma Pharmaceuticals, Inc. (STSA)
Ubrogepant	AbbVie Inc. (ABBV)
Xeomin	Cidara Therapeutics, Inc. (CDTX)
Xeomin	Revance Therapeutics, Inc. (RVNC)
Xeomin	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(9)

Preclinical(5)

Drug	Company
abp-450	AEON Biopharma, Inc. (AEON)
ald1910	ALDER BIOPHARMACEUTICALS INC (ALDR)
Cannabis Genomic Study	WEED, INC. (BUDZ)
rizatriptan spray formulation	Pelthos Therapeutics Inc. (PTHS)
ub-313	Vaxxinity, Inc. (VAXX)

Unknown(6)

Drug	Company
Cannabis Genomic Study (Sangre AT, LLC)	WEED, INC. (BUDZ)
Emgality	Organon & Co. (OGN)
InFoods® platform (other disease targets)	BIOMERICA INC (BMRA)
Rayvow	Organon & Co. (OGN)
rimegepant	PFIZER INC (PFE)
various	PFIZER INC (PFE)

BLA Filed(2)

Drug	Company
eptinezumab	ALDER BIOPHARMACEUTICALS INC (ALDR)
m207	Zosano Pharma Corp (ZSAN)

N/A(2)

Drug	Company
Pharmacological prophylaxis	Structure Therapeutics Inc. (GPCR)
prochlorperazine and benadryl IV	UNITED THERAPEUTICS Corp (UTHR)

Phase 4(7)

Drug	Company
Botulinum toxin type A	Revance Therapeutics, Inc. (RVNC)
Botulinum Toxin Type A 100U	Revance Therapeutics, Inc. (RVNC)
Botulinum Toxin Type A 200U	Revance Therapeutics, Inc. (RVNC)
CGRP mAbs and onabotulinumtoxin A	Revance Therapeutics, Inc. (RVNC)
Diphenhydramine	UNITED THERAPEUTICS Corp (UTHR)
erenumab	AMGEN INC (AMGN)
Haloperidol	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 69 drugs in development for Migraine across 40 companies.

There are 34 clinical trials targeting Migraine tracked by BioSniper.

The estimated prevalence of Migraine is approximately 15000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.